Skip to main content

Table 1 Baseline characteristics of the patients

From: Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients

Variables ETV
(n = 105)
TDF
(n = 105)
P
Age (years) 47.0 ± 12.0 45.5 ± 11.9 0.396
Sex (male, %) 64 (61.0) 67 (63.8) 0.776
HBeAg-positive (%) 58 (55.2) 63 (50.0) 0.577
Disease status;
CHB/LC (%)
62/43
(59.0/41.0)
64/41
(61.0/39.0)
0.888
MELD (<7/7-13/>13, %) 73/26/6
(69.5/24.8/5.7)
71/33/1
(67.6/31.4/1.0)
0.800
Serum ALT (IU/L) 179.5 ± 253.0 232.3 ± 427.7 0.278
Serum total bilirubin (mg/dL) 1.20 ± 1.74 1.06 ± 1.29 0.507
Serum albumin (g/dL) 4.11 ± 0.56 4.10 ± 0.53 0.905
INR 1.12 ± 0.19 1.11 ± 0.17 0.927
Serum HBV DNA level (log10 IU/mL) 6.56 ± 1.33 6.66 ± 1.26 0.564
Duration of follow-up (months) 27.0 ± 7.2 23.6 ± 5.2  
  1. Continuous variables were expressed as mean ± standard deviation
  2. ALT alanine aminotransferase, CHB chronic hepatitis B, ETV entecavir, HBeAg hepatitis B e antigen, HBV hepatitis B virus, INR international normalized ratio, LC liver cirrhosis, MELD model for end stage liver disease, TDF tenofovir